- Home
- IMNN vs ORIS Comparison
IMNN vs ORIS Comparison
Compare IMNN & ORIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- ORIS
- Stock Information
- Founded
- IMNN 1982
- ORIS 2014
- Country
- IMNN United States
- ORIS China
- Employees
- IMNN N/A
- ORIS N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- ORIS Farming/Seeds/Milling
- Sector
- IMNN Health Care
- ORIS Consumer Staples
- Exchange
- IMNN Nasdaq
- ORIS Nasdaq
- Market Cap
- IMNN 12.1M
- ORIS 13.6M
- IPO Year
- IMNN 1985
- ORIS 2024
- Fundamental
- Price
- IMNN $7.61
- ORIS $0.14
- Analyst Decision
- IMNN Buy
- ORIS
- Analyst Count
- IMNN 2
- ORIS 0
- Target Price
- IMNN $210.00
- ORIS N/A
- AVG Volume (30 Days)
- IMNN 405.2K
- ORIS 14.3M
- Earning Date
- IMNN 08-05-2025
- ORIS 02-21-2025
- Dividend Yield
- IMNN N/A
- ORIS N/A
- EPS Growth
- IMNN N/A
- ORIS N/A
- EPS
- IMNN N/A
- ORIS 0.17
- Revenue
- IMNN N/A
- ORIS $15,014,000.00
- Revenue This Year
- IMNN N/A
- ORIS N/A
- Revenue Next Year
- IMNN N/A
- ORIS N/A
- P/E Ratio
- IMNN N/A
- ORIS $0.86
- Revenue Growth
- IMNN N/A
- ORIS N/A
- 52 Week Low
- IMNN $5.55
- ORIS $0.12
- 52 Week High
- IMNN $54.75
- ORIS $56.01
- Technical
- Relative Strength Index (RSI)
- IMNN 38.74
- ORIS N/A
- Support Level
- IMNN $6.51
- ORIS N/A
- Resistance Level
- IMNN $8.10
- ORIS N/A
- Average True Range (ATR)
- IMNN 1.32
- ORIS 0.00
- MACD
- IMNN 0.20
- ORIS 0.00
- Stochastic Oscillator
- IMNN 20.04
- ORIS 0.00
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About ORIS Oriental Rise Holdings Limited Ordinary Shares
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).